Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This study is the first to identify a de novo heterozygous frameshift insertion variant in the ARID1B gene as a cause of Coffin-Siris syndrome with an association to excessive early-onset high myopia.

This abstract discusses Ignite Amazonian Sunrise Drops, a weight loss supplement that claims to boost metabolism using natural ingredients but reports no new scientific findings.

This advertisement for Ignite Amazonian Sunrise Drops presents a supplement with natural ingredients claimed to boost metabolism and aid weight loss, but reports no clinical trial results.

This article describes the promoted benefits of Ignite Amazonian Sunrise Drops for weight management and metabolism, but it reports no new scientific results.

The antidepressant escitalopram likely caused hair loss in a patient.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This review discusses the importance of recognizing and treating psychiatric conditions in dermatology patients, offering practical recommendations for dermatologists to manage psychocutaneous diseases effectively, but reports no new clinical results.

This review discusses OCD spectrum disorders with dermatological symptoms, emphasizing their clinical features, neurobiology, and treatment options, while noting the need for more controlled studies.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This case report describes a 66-year-old male with benign prostatic hyperplasia who developed urinary incontinence after starting venlafaxine, which resolved upon discontinuation of the medication.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

This review discusses the clinical features of trichotillomania and the challenges in its diagnosis and treatment, reporting no new clinical findings while highlighting the need for specialized therapy and better therapeutic options.

This review discusses the potential for SSRIs to cause serious skin reactions and suggests considering alternative antidepressants if such reactions occur.

This review discusses adverse cutaneous drug reactions associated with antidepressants and provides guidance on managing these reactions, but it reports no new clinical findings; the authors recommend cautious use and alternative treatment if reactions occur.

This review discusses the complex interplay between the nervous system and skin conditions, highlighting various treatment strategies, but reports no new research findings.

This review discusses psychocutaneous syndromes, detailing their classifications and management strategies, but reports no new clinical findings; it underscores dermatologists' role in these cases.

This review discusses the diagnostic and treatment challenges of trichotillomania and emphasizes the need for better-designed studies to optimize treatment approaches.

This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.

This review discusses common psychodermatologic conditions and provides practical diagnostic and therapeutic recommendations but reports no new results; the authors emphasize the challenge of treating patients who lack insight into their psychiatric symptoms.

This preliminary study suggests that baseline central serotonin turnover, indicated by CSF 5-HIAA levels, may influence treatment response to serotonin re-uptake inhibitors in women with trichotillomania.

This review discusses trichotillomania, its prevalence, and treatment options, emphasizing that many sufferers experience delays in treatment due to secrecy and shame, but reports no new research findings.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This review discusses the role of gut steroids in communicating with the gut microbiota and their potential implications in treating gastrointestinal disorders and related brain conditions, suggesting new perspectives on steroid molecules as therapeutic agents.

This review discusses trichotillomania, including its diagnosis and management, and emphasizes the importance of a psychiatry-dermatology liaison alongside behavioral therapy and pharmacological options.

The authors report a dementia patient who developed severe trichotillomania unresponsive to SSRIs, which improved with quetiapine; they suggest dopamine blockade may manage such symptoms in dementia.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This case report observed that an adolescent female experienced hair loss with fluoxetine and sertraline, which resolved with venlafaxine, suggesting potential alopecia as an adverse reaction to these SSRIs.